Familial Cancer

, Volume 12, Issue 2, pp 217–228

Prediction models in Lynch syndrome

Original Article

Abstract

Prediction models for the identification of Lynch syndrome have been developed to quantify an individual’s risk of carrying a mismatch repair gene mutation and help clinicians decide for whom further risk assessment and genetic testing is necessary. There are diverse clinical settings in which a healthcare provider has the opportunity to assess an individual for Lynch syndrome. Prediction models offer a potentially feasible and useful strategy to systematically identify at-risk individuals, whether they are affected with colorectal cancer or not, and to help with management of the implications of molecular and germline test results. Given the complexity of diagnostic information currently available to clinicians involved in identifying and caring for patients with Lynch syndrome, prediction models provide a useful and complementary aid in medical decision-making. Systematic implementation of prediction models estimates should be considered in routine clinical care and at various stages of cancer risk assessment and prevention. In this manuscript, we review the main prediction models developed for Lynch syndrome, focus on their specific features and performance assessed in several validation studies, compare the models with other clinical and molecular strategies for the diagnosis of Lynch syndrome, and discuss their potential uses in clinical practice.

Keywords

Lynch syndrome Prediction models PREMM1,2,6 MMRPro MMRPredict 

References

  1. 1.
    Aarnio M, Mecklin JP, Aaltonen LA, Nyström-Lahti M, Järvinen HJ (1995) Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Int J Cancer 64(6):430–433PubMedCrossRefGoogle Scholar
  2. 2.
    Rodriguez-Bigas MA, Boland CR, Hamilton SR, Henson DE, Jass JR, Khan PM, Lynch H, Perucho M, Smyrk T, Sobin L, Srivastava S (1997) A National Cancer Institute workshop on hereditary nonpolyposis colorectal cancer syndrome: meeting highlights and Bethesda guidelines. J Natl Cancer Inst 89(23):1758–1762PubMedCrossRefGoogle Scholar
  3. 3.
    Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Rüschoff J, Fishel R, Lindor NM, Burgart LJ, Hamelin R, Hamilton SR, Hiatt RA, Jass J, Lindblom A, Lynch HT, Peltomaki P, Ramsey SD, Rodriguez-Bigas MA, Vasen HF, Hawk ET, Barrett JC, Freedman AN, Srivastava S (2004) Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 96(4):261–268PubMedCrossRefGoogle Scholar
  4. 4.
    Park JG, Vasen HF, Park KJ, Peltomaki P, de Leon MP, Rodriguez-Bigas MA, Lubinski J, Beck NE, Bisgaard ML, Miyaki M, Wijnen JT, Baba S, Lynch HT (1999) Suspected hereditary nonpolyposis colorectal cancer: International Collaborative Group on hereditary non-polyposis colorectal cancer (ICG-HNPCC) criteria and results of genetic diagnosis. Dis Colon Rectum 42(6):710–715PubMedCrossRefGoogle Scholar
  5. 5.
    Syngal S, Fox EA, Eng C, Kolodner RD, Garber JE (2000) Sensitivity and specificity of clinical criteria for hereditary non-polyposis colorectal cancer associated mutations in MSH2 and MLH1. J Med Genet 37(9):641–645PubMedCrossRefGoogle Scholar
  6. 6.
    Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P, Nakagawa H, Sotamaa K, Prior TW, Westman J, Panescu J, Fix D, Lockman J, Comeras I, de la Chapelle A (2005) Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 352(18):1851–1860PubMedCrossRefGoogle Scholar
  7. 7.
    Julié C, Trésallet C, Brouquet A, Vallot C, Zimmermann U, Mitry E, Radvanyi F, Rouleau E, Lidereau R, Coulet F, Olschwang S, Frébourg T, Rougier P, Nordlinger B, Laurent-Puig P, Penna C, Boileau C, Franc B, Muti C, Hofmann-Radvanyi H (2008) Identification in daily practice of patients with Lynch syndrome (hereditary nonpolyposis colorectal cancer): revised Bethesda guidelines-based approach versus molecular screening. Am J Gastroenterol 103(11):2825–2835PubMedCrossRefGoogle Scholar
  8. 8.
    Pérez-Carbonell L, Ruiz-Ponte C, Guarinos C, Alenda C, Payá A, Brea A, Egoavil CM, Castillejo A, Barberá VM, Bessa X, Xicola RM, Rodríguez-Soler M, Sánchez-Fortún C, Acame N, Castellví-Bel S, Piñol V, Balaguer F, Bujanda L, De-Castro ML, Llor X, Andreu M, Carracedo A, Soto JL, Castells A, Jover R (2012) Comparison between universal molecular screening for Lynch syndrome and revised Bethesda guidelines in a large population-based cohort of patients with colorectal cancer. Gut 61(6):865–872PubMedCrossRefGoogle Scholar
  9. 9.
    Parsons MT, Buchanan DD, Thompson B, Young JP, Spurdle AB (2012) Correlation of tumour BRAF mutations and MLH1 methylation with germline mismatch repair (MMR) gene mutation status: a literature review assessing utility of tumour features for MMR variant classification. J Med Genet 49(3):151–157PubMedCrossRefGoogle Scholar
  10. 10.
    Piñol V, Castells A, Andreu M, Castellví-Bel S, Alenda C, Llor X, Xicola RM, Rodríguez-Moranta F, Payá A, Jover R, Bessa X (2005) Gastrointestinal Oncology Group of the Spanish Gastroenterological Association. Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. JAMA 293(16):1986–1994PubMedCrossRefGoogle Scholar
  11. 11.
    Moreira L, Balaguer F, Lindor N, de la Chapelle A, Hampel H, Aaltonen LA, Hopper JL, Le Marchand L, Gallinger S, Newcomb PA, Haile R, Thibodeau SN, Gunawardena S, Jenkins MA, Buchanan DD, Potter JD, Baron JA, Ahnen DJ, Moreno V, Andreu M, de Leon MP, Rustgi AK, Castells A (2012) EPICOLON Consortium. Identification of Lynch syndrome among patients with colorectal cancer. JAMA 308(15):1555–1565PubMedCrossRefGoogle Scholar
  12. 12.
    Grover S, Stoffel EM, Bussone L, Tschoegl E, Syngal S (2004) Physician assessment of family cancer history and referral for genetic evaluation in colorectal cancer patients. Clin Gastroenterol Hepatol 2(9):813–819PubMedCrossRefGoogle Scholar
  13. 13.
    Flynn BS, Wood ME, Ashikaga T, Stockdale A, Dana GS, Naud S (2010) Primary care physicians’ use of family history for cancer risk assessment. BMC Fam Pract 11:45PubMedCrossRefGoogle Scholar
  14. 14.
    Beamer LC, Grant ML, Espenschied CR, Blazer KR, Hampel HL, Weitzel JN, MacDonald DJ (2012) Reflex immunohistochemistry and microsatellite instability testing of colorectal tumors for Lynch syndrome among US cancer programs and follow-up of abnormal results. J Clin Oncol 30(10):1058–1063PubMedCrossRefGoogle Scholar
  15. 15.
    Wijnen JT, Vasen HF, Khan PM, Zwinderman AH, van der Klift H, Mulder A, Tops C, Møller P, Fodde R (1998) Clinical findings with implications for genetic testing in families with clustering of colorectal cancer. N Engl J Med 339(8):511–518PubMedCrossRefGoogle Scholar
  16. 16.
    Lipton LR, Johnson V, Cummings C, Fisher S, Risby P, Eftekhar Sadat AT, Cranston T, Izatt L, Sasieni P, Hodgson SV, Thomas HJ, Tomlinson IP (2004) Refining the Amsterdam Criteria and Bethesda Guidelines: testing algorithms for the prediction of mismatch repair mutation status in the familial cancer clinic. J Clin Oncol 22(24):4934–4943PubMedCrossRefGoogle Scholar
  17. 17.
    Barnetson RA, Tenesa A, Farrington SM, Nicholl ID, Cetnarskyj R, Porteous ME, Campbell H, Dunlop MG (2006) Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. N Engl J Med 354:2751–2763PubMedCrossRefGoogle Scholar
  18. 18.
    Chen S, Wang W, Lee S, Nafa K, Lee J, Romans K, Watson P, Gruber SB, Euhus D, Kinzler KW, Jass J, Gallinger S, Lindor NM, Casey G, Ellis N, Giardiello FM, Offit K, Parmigiani G (2006) Colon Cancer Family Registry. Prediction of germline mutations and cancer risk in the Lynch syndrome. JAMA 296:1479–1487PubMedCrossRefGoogle Scholar
  19. 19.
    Balmaña J, Stockwell DH, Steyerberg EW, Stoffel EM, Deffenbaugh AM, Reid JE, Ward B, Scholl T, Hendrickson B, Tazelaar J, Burbidge LA, Syngal S (2006) Prediction of MLH1 and MSH2 mutations in Lynch syndrome. JAMA 296:1469–1478PubMedCrossRefGoogle Scholar
  20. 20.
    Kastrinos F, Steyerberg EW, Mercado R, Balmaña J, Holter S, Gallinger S, Siegmund KD, Church JM, Jenkins MA, Lindor NM, Thibodeau SN, Burbidge LA, Wenstrup RJ, Syngal S (2011) The PREMM(1,2,6) model predicts risk of MLH1, MSH2, and MSH6 germline mutations based on cancer history. Gastroenterology 140(1):73–81PubMedCrossRefGoogle Scholar
  21. 21.
    Balaguer F, Balmaña J, Castellví-Bel S, Steyerberg EW, Andreu M, Llor X, Jover R, Syngal S, Castells A (2008) Gastrointestinal Oncology Group of the Spanish Gastroenterological Association. Validation and extension of the PREMM1,2 model in a population-based cohort of colorectal cancer patients. Gastroenterology 134(1):39–46PubMedCrossRefGoogle Scholar
  22. 22.
    Balmaña J, Balaguer F, Castellví-Bel S, Steyerberg EW, Andreu M, Llor X, Jover R, Castells A, Syngal S (2008) Gastrointestinal Oncology Group of the Spanish Gastroenterological Association. Comparison of predictive models, clinical criteria and molecular tumor screening for the identification of patients with Lynch syndrome in a population-based cohort of colorectal cancer patients. J Med Genet 45:557–563PubMedCrossRefGoogle Scholar
  23. 23.
    Green RC, Parfrey PS, Woods MO, Younghusband HB (2009) Prediction of Lynch syndrome in consecutive patients with colorectal cancer. J Natl Cancer Inst 101:331–340PubMedCrossRefGoogle Scholar
  24. 24.
    Kastrinos F, Steyerberg EW, Balmaña J, Mercado R, Gallinger S, Haile R, Casey G, Hopper JL, Lemarchand L, Lindor NM, Newcomb PA, Thibodeau SN, Syngal S, The Colon Cancer Family Registry (2012) Comparison of the clinical prediction model PREMM1,2,6 and molecular testing for the systematic identification of Lynch syndrome in colorectal cancer. Gut [Epub ahead of print]Google Scholar
  25. 25.
    Khan O, Blanco A, Conrad P, Gulden C, Moss TZ, Olopade OI, Kupfer SS, Terdiman J (2011) Performance of Lynch syndrome predictive models in a multi-center US referral population. Am J Gastroenterol 106:1822–1827PubMedCrossRefGoogle Scholar
  26. 26.
    Pouchet CJ, Wong N, Chong G, Sheehan MJ, Schneider G, Rosen-Sheidley B, Foulkes W, Tischkowitz M (2009) A comparison of models used to predict MLH1, MSH2 and MSH6 mutation carriers. Ann Oncol 20:681–688PubMedCrossRefGoogle Scholar
  27. 27.
    Monzon JG, Cremin C, Armstrong L, Nuk J, Young S, Horsman DE, Garbutt K, Bajdik CD, Gill S (2010) Validation of predictive models for germline mutations in DNA mismatch repair genes in colorectal cancer. Int J Cancer 126:930–939PubMedGoogle Scholar
  28. 28.
    Tresallet C, Brouquet A, Julié C, Beauchet A, Vallot C, Ménégaux F, Mitry E, Radvanyi F, Malafosse R, Rougier P, Nordlinger B, Laurent-Puig P, Boileau C, Emile JF, Muti C, Penna C, Hofmann-Radvanyi H (2012) Evaluation of predictive models in daily practice for the identification of patients with Lynch syndrome. Int J Cancer 130(6):1367–1377PubMedCrossRefGoogle Scholar
  29. 29.
    Ladabaum U, Wang G, Terdiman J, Blanco A, Kuppermann M, Boland CR, Ford J, Elkin E, Phillips KA (2011) Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. Ann Intern Med 155:69–79PubMedCrossRefGoogle Scholar
  30. 30.
    Dinh TA, Rosner BI, Atwood JC, Boland CR, Syngal S, Vasen HF, Gruber SB, Burt RW (2011) Health benefits and cost-effectiveness of primary genetic screening for Lynch syndrome in the general population. Cancer Prev Res 4:9–22CrossRefGoogle Scholar
  31. 31.
    National Comprehensive Cancer Network Guidelines Version 2.2012 Colorectal Cancer Screening. MS-15; Retrieved from http://www.nccn.org/clinical.asp. Accessed November 2012

Copyright information

© Springer Science+Business Media Dordrecht 2013

Authors and Affiliations

  • Fay Kastrinos
    • 1
    • 2
    • 7
  • Judith Balmaña
    • 3
  • Sapna Syngal
    • 4
    • 5
    • 6
  1. 1.Herbert Irving Comprehensive Cancer CenterColumbia University Medical CenterNew YorkUSA
  2. 2.Division of Digestive and Liver DiseasesColumbia University Medical CenterNew YorkUSA
  3. 3.Department of Medical Oncology, Hospital Vall d’HebronUniversitat Autònoma de BarcelonaBarcelonaSpain
  4. 4.Population Sciences DivisionDana-Farber Cancer InstituteBostonUSA
  5. 5.Division of GastroenterologyBrigham and Women’s HospitalBostonUSA
  6. 6.Harvard Medical SchoolBostonUSA
  7. 7.Columbia University College of Physicians and SurgeonsNew YorkUSA

Personalised recommendations